Disclosure of Conflicts of Interest

In accordance with policies set forth by the Accreditation Council for Continuing Medical Education (ACCME), Center for Independent Healthcare Education requires all faculty members and spouses/significant others with an opportunity to affect the content of a continuing education activity to disclose any relevant financial relationships during the past 12 months with commercial interests. A commercial interest is any entity producing, marketing, reselling, or distributing healthcare goods or services consumed by or used on patients. Relationships with commercial interests and conflicts of interest resulting from those relationships must be revealed to the audience and resolved prior to the activity.

Relevant relationships include roles such as speaker, author, consultant, independent contractor (including research), employee, investor, advisory committee member, board member, review panelist, and investigator. If a potential speaker or author indicates a possible conflict of interest, the conflict will be resolved by choosing another speaker or author for that topical area, or the slides, handouts, and/or monograph will be reviewed and approved by a qualified commercially disinterested peer.

Faculty

Roy F. Chemaly, MD, MPH, FIDSA, FACP

Professor of Medicine, Director, Infection Control Section; Director of Clinical Virology, Department of ID/IC/EH, University of Texas MD Anderson Cancer Center, Houston, Texas

Disclosures

Disclosure: Roy F. Chemaly, MD, MPH, FIDSA, FACP, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Merck & Co., Inc., Chimerix, Astellas, Oxford Immunotec.
Received grants for clinical research from: Merck & Co., Inc., Chimerix, Shire, Novartis.
Dr. Chemaly discusses the off-label uses of the following: letermovir, maribavir, and brincidofovir

Sanjeet Singh Dadwal, MD

Associate Clinical Professor of Medicine, Division of Infectious Disease; Head, Antimicrobial Stewardship Program; Co-Lead Infectious Disease, Transplant Disease Team, City of Hope National Medical Center, Duarte, California

Disclosures

Disclosure: Sanjeet Singh Dadwal, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Merck & Co., Inc.
Dr. Dadwal does not discuss the off-label uses of any products.

Camille Nelson Kotton, MD

Clinical Director, Transplant and Immunocompromised Host, Infectious Diseases, Massachusetts General Hospital; Associate Professor, Harvard Medical School, Boston, Massachusetts

Disclosures

Disclosure: Camille Nelson Kotton, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Roche Diagnostics, Chimerix, Merck & Co., Inc., Cellestis-Qiagen, Oxford Immunotec, Shire
Served as an adjudication committee member: Merck & Co., Inc., Astellas, Shire.
Received grants for clinical research from: Oxford Immnunotec.
Dr. Kotton discusses the off-label uses of the following: diagnostics and therapeutics.

No (other) speakers, authors, planners, or content reviewers have any relevant financial relationships to disclose. No (other) speakers or authors will discuss off-label use of a product.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

CME / CE

Prevention Strategies to Minimize the Clinical Burden of CMV in Transplant Recipients: An ID Update

Authors: Roy F. Chemaly, MD, MPH, FIDSA, FACP; Sanjeet Singh Dadwal, MD; Camille Nelson Kotton, MD
CME / CE Released: 12/13/2017
THIS ACTIVITY HAS EXPIRED
Valid for credit through: 12/13/2018

Start Activity

Target Audience and Goal Statement

Long-term success of transplant recipients requires an interdisciplinary approach that includes all healthcare providers involved in the management of these patients to prevent and treat CMV viremia. Therefore, this continuing medical education activity targets ID clinicians involved in the care of transplant recipients. These clinicians include ID physicians and pharmacists, clinical microbiologists, nurses, and allied healthcare providers.

Cytomegalovirus (CMV) remains a significant pathogen in certain patient populations. Transplant recipients are at exceptional risk, and CMV infection can lead to myelosuppression, tissue-invasive disease, graft rejection/failure, and development of other opportunistic infections that can contribute to mortality. Long-term clinical success requires effective prevention and treatment of CMV. Prevention can be accomplished through antiviral prophylaxis or preemptive approaches. The development of advanced diagnostic tools along with newer antiviral agents have the potential to improve protection against CMV in vulnerable patients. To improve patient outcomes, an interdisciplinary approach involving physicians, pharmacists, microbiologists, nurses, and allied healthcare providers is needed to contribute at all stages of patient care. This activity reviews the latest clinical evidence on the diagnosis, monitoring, and prevention of CMV infection and disease, and will highlight the latest advances in diagnostics and antiviral development that can be used to improve long-term patient outcomes.

Please note: On November 9, 2017, FDA approved letermovir for prophylaxis of CMV infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT).

Upon completion of this activity, participants will be able to:

Identify patient factors attributed to increased risk for CMV following transplantation
Use advanced diagnostic techniques to monitor CMV status in transplant recipients and to assess the recipient’s potential to mount an effective immune response to guide post-transplantation decisions
Evaluate new and emerging preemptive and prophylactic approaches aimed at minimizing the burden and risk of CMV among transplantation recipients

Disclosures

Disclosure of Conflicts of Interest

Faculty

Roy F. Chemaly, MD, MPH, FIDSA, FACP

Professor of Medicine, Director, Infection Control Section; Director of Clinical Virology, Department of ID/IC/EH, University of Texas MD Anderson Cancer Center, Houston, Texas

Disclosures

Disclosure: Roy F. Chemaly, MD, MPH, FIDSA, FACP, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Merck & Co., Inc., Chimerix, Astellas, Oxford Immunotec.
Received grants for clinical research from: Merck & Co., Inc., Chimerix, Shire, Novartis.
Dr. Chemaly discusses the off-label uses of the following: letermovir, maribavir, and brincidofovir

Sanjeet Singh Dadwal, MD

Associate Clinical Professor of Medicine, Division of Infectious Disease; Head, Antimicrobial Stewardship Program; Co-Lead Infectious Disease, Transplant Disease Team, City of Hope National Medical Center, Duarte, California

Disclosures

Disclosure: Sanjeet Singh Dadwal, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Merck & Co., Inc.
Dr. Dadwal does not discuss the off-label uses of any products.

Camille Nelson Kotton, MD

Clinical Director, Transplant and Immunocompromised Host, Infectious Diseases, Massachusetts General Hospital; Associate Professor, Harvard Medical School, Boston, Massachusetts

Disclosures

Disclosure: Camille Nelson Kotton, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Roche Diagnostics, Chimerix, Merck & Co., Inc., Cellestis-Qiagen, Oxford Immunotec, Shire
Served as an adjudication committee member: Merck & Co., Inc., Astellas, Shire.
Received grants for clinical research from: Oxford Immnunotec.
Dr. Kotton discusses the off-label uses of the following: diagnostics and therapeutics.

No (other) speakers, authors, planners, or content reviewers have any relevant financial relationships to disclose. No (other) speakers or authors will discuss off-label use of a product.

Accreditation Statements

For Physicians

This activity is jointly provided by the Center for Independent Healthcare Education and Vemco MedEd.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Center for Independent Healthcare Education (Center) and Vemco MedEd.

Center is accredited by the ACCME to provide continuing medical education for physicians.

Center designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Contact This Provider

For Pharmacists

Center for Independent Healthcare Education is accredited by the Accreditation Council for Pharmacy Education as a provider for continuing pharmacy education.

Center has assigned 1.5 contact hours (0.15 CEUs) of continuing pharmacy education credits for participating in this activity. ACPE UAN: 0473-9999-17-015-H01-P

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.
Pharmacists: Credit will be uploaded to CPE Monitor at the beginning of every month.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / CE

Prevention Strategies to Minimize the Clinical Burden of CMV in Transplant Recipients: An ID Update

Authors: Roy F. Chemaly, MD, MPH, FIDSA, FACP; Sanjeet Singh Dadwal, MD; Camille Nelson Kotton, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED

CME / CE Released: 12/13/2017

Valid for credit through: 12/13/2018

processing....

Before you begin, please answer the questions in this brief questionnaire.

Page 1 of 2

CME / CE Information Download Slides

PDF Downloads

CMV Abbreviations

Print
Like Tweet